Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Quintiles Opens First India Lab and Hunts for New Business

This article was originally published in PharmAsia News

Executive Summary

OutsourcingPharma.com (France) (04/10/07) Barnes, Kirsty

OutsourcingPharma.com (France) (04/10/07) Barnes, Kirsty

International pharmaceutical company Quintiles has opened a central pharmaceutical laboratory in Mumbai, India, after 10 years of managing multiple smaller operations around India. Quintiles CEO Dennis Gillings says the opening signifies "the acceptance of India as a center for clinical research." The new lab will conduct core clinical research, offer testing for certification by the College of American Pathologists, and host an electrocardiogram and data management businesses. Quintiles subsidiary NovaQuest is seeking drug development deals in India and is in talks with some companies, says Gillings. To date Quintiles has conducted over 700 global clinical trials in India, and has a 750-person research staff there. (Click here for more )
Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC066124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By